171 related articles for article (PubMed ID: 36508298)
41. European Perspective on 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: Proceedings of an Interactive International Symposium.
Luster M; Aktolun C; Amendoeira I; Barczyński M; Bible KC; Duntas LH; Elisei R; Handkiewicz-Junak D; Hoffmann M; Jarząb B; Leenhardt L; Musholt TJ; Newbold K; Nixon IJ; Smit J; Sobrinho-Simões M; Sosa JA; Tuttle RM; Verburg FA; Wartofsky L; Führer D
Thyroid; 2019 Jan; 29(1):7-26. PubMed ID: 30484394
[TBL] [Abstract][Full Text] [Related]
42. Eighth edition of tumor-node-metastasis staging system improve survival predictability for papillary, but not follicular thyroid carcinoma: A multicenter cohort study.
Kim M; Kim HI; Jeon MJ; Kim HK; Kim EH; Yi HS; Kim ES; Kim H; Kim BH; Kim TY; Kim SW; Kang HC; Kim WB; Chung JH; Shong YK; Kim TH; Kim WG
Oral Oncol; 2018 Dec; 87():97-103. PubMed ID: 30527251
[TBL] [Abstract][Full Text] [Related]
43. Evaluating the influence of prophylactic central neck dissection on TNM staging and the recurrence risk stratification of cN0 differentiated thyroid carcinoma.
Lin X; Chen X; Jiru Y; Du J; Zhao G; Wu Z
Bull Cancer; 2016 Jun; 103(6):535-40. PubMed ID: 27236850
[TBL] [Abstract][Full Text] [Related]
44. Risk for Thyroid Cancer Recurrence Is Higher in Men Than in Women Independent of Disease Stage at Presentation.
Zahedi A; Bondaz L; Rajaraman M; Leslie WD; Jefford C; Young JE; Pathak KA; Bureau Y; Rachinsky I; Badreddine M; De Brabandere S; Fong H; Maniakas A; Van Uum S
Thyroid; 2020 Jun; 30(6):871-877. PubMed ID: 31524071
[No Abstract] [Full Text] [Related]
45. Prognostic value of the eighth edition AJCC TNM classification for differentiated thyroid carcinoma.
Kim TH; Kim YN; Kim HI; Park SY; Choe JH; Kim JH; Kim JS; Oh YL; Hahn SY; Shin JH; Kim K; Jeong JG; Kim SW; Chung JH
Oral Oncol; 2017 Aug; 71():81-86. PubMed ID: 28688696
[TBL] [Abstract][Full Text] [Related]
46. Validation of the QTNM staging system for cancer-specific survival in patients with differentiated thyroid cancer.
Mankarios D; Baade P; Youl P; Mortimer RH; Onitilo AA; Russell A; Doi SA
Endocrine; 2014 Jun; 46(2):300-8. PubMed ID: 24174176
[TBL] [Abstract][Full Text] [Related]
47. Improving the prediction of persistent and recurrent differentiated thyroid cancer using the American Thyroid Association 2015 risk stratification system.
Markantes GK; Karakioulaki M; Papanikolopoulou S; Theodoropoulou A; Markou KB; Vagenakis AG; Spyridonidis T; Goulis DG; Michalaki MA
Hormones (Athens); 2021 Dec; 20(4):761-768. PubMed ID: 34383288
[TBL] [Abstract][Full Text] [Related]
48. Age, thyroglobulin levels and ATA risk stratification predict 10-year survival rate of differentiated thyroid cancer patients.
Kelly A; Barres B; Kwiatkowski F; Batisse-Lignier M; Aubert B; Valla C; Somda F; Cachin F; Tauveron I; Maqdasy S
PLoS One; 2019; 14(8):e0221298. PubMed ID: 31425569
[TBL] [Abstract][Full Text] [Related]
49. Comparison of the abilities of staging and risk stratification systems to predict the long-term structural recurrence in patients with differentiated thyroid carcinoma after total thyroidectomy and radioactive iodine remnant ablation.
Nam KT; Park JH; Moon GS; Yoon JH
Gland Surg; 2021 Jul; 10(7):2200-2210. PubMed ID: 34422591
[TBL] [Abstract][Full Text] [Related]
50. Refining the tumor-node-metastasis staging system for individualized treatment of differentiated thyroid carcinoma.
Kim YN; Kim M; Ahn HS; Kim K; Park SY; Kim HI; Jeon MJ; Kim WG; Kim SW; Kim WB; Chung JH; Shong YK; Kim TY; Kim TH
Oral Oncol; 2019 Feb; 89():8-13. PubMed ID: 30732964
[TBL] [Abstract][Full Text] [Related]
51. Modification of the eight-edition tumor-node-metastasis staging system with N1b for papillary thyroid carcinoma: A multi-institutional cohort study.
Kim M; Kim HK; Kim HI; Kim EH; Jeon MJ; Yi HS; Kim ES; Kim H; Kim TH; Kim BH; Kim TY; Kang HC; Kim WB; Chung JH; Shong YK; Kim SW; Kim WG
Oral Oncol; 2018 Nov; 86():48-52. PubMed ID: 30409319
[TBL] [Abstract][Full Text] [Related]
52. Implementing the Modified 2009 American Thyroid Association Risk Stratification System in Thyroid Cancer Patients with Low and Intermediate Risk of Recurrence.
Pitoia F; Jerkovich F; Urciuoli C; Schmidt A; Abelleira E; Bueno F; Cross G; Tuttle RM
Thyroid; 2015 Nov; 25(11):1235-42. PubMed ID: 26132983
[TBL] [Abstract][Full Text] [Related]
53. Optimal cut-off age in the TNM Staging system of differentiated thyroid cancer: is 55 years better than 45 years?
Kim M; Kim YN; Kim WG; Park S; Kwon H; Jeon MJ; Ahn HS; Jung SH; Kim SW; Kim WB; Chung JH; Shong YK; Kim TH; Kim TY
Clin Endocrinol (Oxf); 2017 Mar; 86(3):438-443. PubMed ID: 27731521
[TBL] [Abstract][Full Text] [Related]
54. Projecting Survival in Papillary Thyroid Cancer: A Comparison of the Seventh and Eighth Editions of the American Joint Commission on Cancer/Union for International Cancer Control Staging Systems in Two Contemporary National Patient Cohorts.
Pontius LN; Oyekunle TO; Thomas SM; Stang MT; Scheri RP; Roman SA; Sosa JA
Thyroid; 2017 Nov; 27(11):1408-1416. PubMed ID: 28891405
[TBL] [Abstract][Full Text] [Related]
55. A Comparison of the Seventh and Eighth Editions of the AJCC Staging Systems to Predict Recurrence in Papillary Thyroid Microcarcinoma.
Chen Z; Ruan J; Yao Y; Wen L; Mao Z; Chen S; Zhu H; Zhao Y; Li Z; Fahey TJ; Teng L; Wang W
Ann Surg Oncol; 2021 Oct; 28(11):6564-6571. PubMed ID: 33521903
[TBL] [Abstract][Full Text] [Related]
56. Dynamic Risk Stratification for Predicting Recurrence in Patients with Differentiated Thyroid Cancer Treated Without Radioactive Iodine Remnant Ablation Therapy.
Park S; Kim WG; Song E; Oh HS; Kim M; Kwon H; Jeon MJ; Kim TY; Shong YK; Kim WB
Thyroid; 2017 Apr; 27(4):524-530. PubMed ID: 27869547
[TBL] [Abstract][Full Text] [Related]
57. A relook at the 8th edition of the AJCC TNM staging system of anaplastic thyroid carcinoma: A SEER-based study.
Xiang J; Wang Z; Sun W; Zhang H
Clin Endocrinol (Oxf); 2021 Apr; 94(4):700-710. PubMed ID: 33368530
[TBL] [Abstract][Full Text] [Related]
58. Ongoing risk stratification for differentiated thyroid cancer (DTC) - stimulated serum thyroglobulin (Tg) before radioiodine (RAI) ablation, the most potent risk factor of cancer recurrence in M0 patients.
Krajewska J; Jarząb M; Czarniecka A; Roskosz J; Kukulska A; Handkiewicz-Junak D; Puch Z; Wygoda Z; Paliczka-Cieślik E; Kropińska A; Gubała E; Jurecka-Lubieniecka B; Jarząb B
Endokrynol Pol; 2016; 67(1):2-11. PubMed ID: 26884109
[TBL] [Abstract][Full Text] [Related]
59. Survival Predictability Between the American Joint Committee on Cancer 8th Edition Staging System and the Barcelona Clinic Liver Cancer Classification in Patients with Hepatocellular Carcinoma.
Chen LJ; Chang YJ; Chang YJ
Oncologist; 2021 Mar; 26(3):e445-e453. PubMed ID: 32969134
[TBL] [Abstract][Full Text] [Related]
60. [Management and dynamic risk stratification of differentiated thyroid cancer].
Huang YC; Li ZJ
Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2019 May; 54(5):389-393. PubMed ID: 31137103
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
